Spinifex Pharmaceuticals is a clinical-stage Australian biotechnology company specialising in the development of products for the treatment of pain.
Phase 2 Program Commences
Spinifex Pharmaceuticals announces the first patients have been treated in its Phase 2 clinical trial of EMA401 in postherpetic neuralgia (PHN).
Latest News & Events
23RD DECEMBER 2011 Spinifex set to present at the Biotech Showcase 2012 conference in San Francisco ... More
6TH DECEMBER 2011 Appointment of Spinifex Non-Executive Chairman. ... More
19TH SEPTEMBER 2011 Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Postherpetic Neuralgia ... More